Antibody & TIDES Summit 2025

Antibody & ADC agenda

The Antibody & ADC agenda offers a dynamic, two-day program spanning cutting-edge antibody engineering, AI in discovery, and next-generation ADC platforms. Day 1 opens with keynote insights into the evolving antibody therapeutics landscape, followed by sessions on bispecific antibody design from Peter Ellmark, Alligator Bioscience, and therapeutic antibody humanization from Nathan Robertson, LifeArc. A standout panel featuring leaders from Genmab, Step Pharma, and LifeArc delves into biomarker integration to bridge preclinical and clinical success. Sessions also explore AI and machine learning in antibody development, including innovations from Michael Mullin, LabGenius, and Barry Duplantis, Ailux. Functional antibody platforms gain the spotlight with presentations on IgE/IgA therapeutics from Kevin Fitzgerald, Epsilogen, and autoregulating T cell engagers from Vincent Muczynski, NovalGen.

On Day 2, Kerstin Hofer, Roche, presents a breakthrough in CNS delivery of conjugated oligonucleotides, which you can read more about in her recent Bioconjugation Insights podcast article here. Manel Kraiem, Skymab, Dominik Brücher, CIS BIOPHARMA, and Philipp Spycher, Araris Biotech, showcase advances in multi-payload and anti-GPCR ADCs. Joost Uitdehaag, Crossfire Oncology, adds further insight into payload innovation and site-specific conjugation chemistry. Strategic panels and roundtables focus on regulatory navigation, manufacturing scale-up, and global market readiness. From discovery to clinical translation, the agenda provides a comprehensive look at the technologies redefining antibody and ADC therapeutics.

TIDES agenda

The TIDES session offers a robust exploration of peptide and oligonucleotide therapeutics across discovery, development, and delivery. The agenda spans cutting-edge topics including mRNA vaccine delivery, peptide immunogenicity, and regulatory impacts on innovation. Highlights include Vusala Ibrahimova, CureVac, on mRNA stability innovations, and Bernard Maillere, The CEA, examining immunogenic responses in endogenous peptides.

Technical session delves into peptide synthesis, with Fernando Alberico and Walter Cabri discussing greener and cost-efficient approaches in SPPS and LPPS. Thought-provoking roundtables tackle delivery bottlenecks, regulatory hurdles, sustainability. And AI adoption across therapeutic pipelines. Jean Ge and Rafael Grochot address regulatory frameworks and CMC complexities, with David Gilot, AstraZeneca, share strategies for safety monitoring in clinical oligonucleotide development.

Clinical advancements are also spotlighted, with Anders Gabrielsen, Ribocure, presenting siRNA delivery breakthroughs and AiCuris sharing Phase I trial data. Sessions on circular RNA therapeutics, supply chain, digitization, and GLP-compliant logistics round out this future-focused program. Together, these sessions offer a panoramic view of the scientific, regulatory, and operational factors shaping the next wave of oligonucleotide and peptide-based medicine.

Whether you’re engineering next-generation antibodies or advancing oligonucleotide and peptide therapeutics, the Antibody & TIDES Summit 2025 is your gateway to cutting-edge antibody design, ADC innovation, AI-driven discovery, scalable synthesis, and regulatory-ready strategies shaping the future of precision biologics and RNA-based medicines.

As a reader of Bioconjugation Insights, you’re entitled to a 15% discount on delegate tickets—just reach out to bronwyn.westmore@imapac.com! You can find out more about the event here.

Additionally, to find out what other bioconjugate events are upcoming, you can find our online Events Calendar here.